Apidra

Apidra

Sanofi

A rapid-acting insulin that users can deliver via vial and syringe, pen, or pump. It is not known if Apidra is safe in children less than 4 years old with type 1 diabetes or in children with type 2 diabetes.


Features


Specs

Insulin Type:
Rapid-acting
Generic Name:
Insulin glulisine
Delivery:
Syringe, pen, or pump
Form:
Analog
Concentrations:
U-100
Onset:
10 to 20 min.
Peak:
30 to 90 min.
Duration:
2 to 4 hours